Close
CDMO Safety Testing 2026
Novotech

Indian state plans non-generic drugs procurement for government hospitals

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

Made Smarter Advances AI in Manufacturing with New Toolkit

A new initiative from Made Smarter is aiming to...

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.
- Advertisement -

Indian state of Uttar Pradesh is planning to procure non-generic drugs directly from the manufacturing companies for usage in government hospitals in the state.

The state government is formulating a new drug policy that will allow the state health department to procure these drugs for government hospitals, unlike earlier the department used to procure only generic drugs manufactured by companies selected in the drug tender process at the state level.

Principal Secretary of Health and Family Welfare Sanjay Agarwal was quoted by expressindia.com as saying that the idea behind procurement of non-generic drugs is to provide the best quality drugs for chronic diseases in government hospitals.

“The proposal was approved by state’s Health Minister Ahmad Hasan, who wanted that the best quality drugs should also reach the poor people,” said Agarwal.

The state government has allocated a budget of INR45 crore ($8.13m) for procurement of 22 non-generic drugs listed by the department, which will used for ailments like diabetes, cardiac disease, blood pressure as well as some essential anti-biotic drugs, reports the website.

“The companies will enter into a contract with the department wherein they will have to certify that they would not sell these drugs to any other party at a cost lower than the price they are supplying the drugs to UP,” he added.

The non-generic drugs, to be procured by the department, will cost about half the cost of drugs available in the market, according to Agarwal.

Latest stories

Related stories

Made Smarter Advances AI in Manufacturing with New Toolkit

A new initiative from Made Smarter is aiming to...

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.

Gene Expression Systems Explained for Biotech Founders

Choosing a gene expression system is one of the earliest and most consequential manufacturing decisions a biotech founder will make yet it is often made without fully understanding what is at stake. This article breaks down the key expression platforms used in biologic drug development, what differentiates them technically and commercially, and why the choice you make now will follow your program all the way to the clinic and beyond.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป